 The hypothesis that the investigators propose in this pilot study is that intake of DAG oil, compared to TAG oil will result in a lower LDL-C, and lower LDL-CHDL-C ratio, as well as a reduction in TG levels. Given the significance of such findings, if confirmed, the investigators will evaluate other important clinical biomarkers for chronic disease CV Disease, type 2 diabetes, metabolic syndrome, such as insulin sensitivity and inflammation as determined by C-reactive protein CRP, interleukin IL-1, IL-6 tumor necrosis factor-alpha TNF-α, which also may be beneficially affected by consumption of the palm DAG oil. During the pilot study, the investigators will reserve serumplasma samples so that these additional assays may be run upon approval of the modification. 